A Prospective Single-Center Study on Desidustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), in the Management of Anemia in Dialysis-Dependent CKD

Background: Erythropoietin analogous is the backbone of the treatment of dialysis-dependent CKD –Anemia. Recently in India, Desidustat (Oxemia®) a HIF PHI approved by DCGI in dialysis-dependent and Non dialysis-dependent CKD Anemia. The current study enroutes the outcome of the usage of desidustat in DD-CKD Anemia patients. Methods: We analyzed data of patients who were receiving Desidustat 100 mg thrice weekly for correction of Anemia at our center. Patients were followed up regularly for Anemia parameters. Results: In the current study, we enrolled data from 85 patients at our center. The majority of 61 (71.7%) were male, and 24 (28.2%) were female. The mean age of participants was 51.27±14 years. The majority, 66 (77.6%), belong to the middle socioeconomic background. All the patients analyzed received three-time maintenance hemodialysis at our center. Patients with ESRD 71 (83.5%), hypertension 83 (97.6%), diabetic nephropathy 42 (49.4%), PVD 3 (3.5%), Alport syndrome 1 (1.1%), and CVD 1 (1.1%). The baseline serum creatinine of the patients was 6.4±1.5 mg/dl. Serum Iron 29.51±7.94, TSAT 25.06 ± 6.9, and Serum Ferritin 89.34 ± 39.19. In the present study, out of 85 patients, 63 (74.1%) responded with the treatment of anemia, while 22 (25.6%) showed a low rise in Hb with desidustat treatment, as shown in figure 1. In the present study, out of 85 patients, 10 (11.7%) underwent renal transplantation and 3 (3.5%) expired. The reason for low Hb in 22 patients can be due to iron depletion. Gastrointestinal ADRs were observed with Desidustat therapy, which was treated appropriately. Conclusion: The treatment of dialysis-dependent CKD anemia with Desidustat showed a promising response rate. Ensuring adequate iron repletion is crucial for optimizing the response to HIF-PHI treatment